Welcome to SPP2395

SPP2395 is a collaboratively supported priority programme on microglia research. With ~30 principal investigators in two funding periods, we are driving 36 innovative projects across more than 20 research institutes in Germany, Israel, the United Kingdom, Switzerland and Finland. Together, we advance rigorous, transparent science to deepen our understanding of microglia in health and disease.


Our Mission

Microglia are the resident macrophages of the CNS, coordinating homeostatic regulation and mounting first-line immune responses. After two decades revealing their heterogeneity, the field is moving beyond simple “homeostatic” versus “disease-associated” labels toward context-aware biology in intact tissue. SPP2395 prioritizes in vivo investigation and the translation of preclinical insights using human post-mortem tissue, humanized mouse models, iPSC-derived human microglia, and patient data.


News

New Funding Period officially started. SPP2395 held its second kick-off meeting in Berlin on September 8–9, welcoming 12 new principal investigators to the consortium. Over two days, concise project updates, in-depth Q&A, and interactive sessions on microglia research and translational pipelines sparked lively discussion on shared resources, data standards, and reproducibility. The meeting strengthened collaboration across labs and set strong momentum for the next phase of SPP2395.

Upcoming Events